Phase III trial of pracinostat in acute myeloid leukaemia discontinued

The decision to terminate the study was made after an interim futility analysis determined it was unlikely to meet the primary endpoint of overall survival compared to the control group. Pracinostat has been granted orphan drug designation in the US and EU for this indication.


Biospace Inc.